ALEXANDRIA, Virginia — The American Association for the Study of Liver Diseases (AASLD) is pleased to announce the appointment of Naga Chalasani, MD, FAASLD, of Indiana University School of Medicine, and Laura E. Nagy, PhD, FAASLD, of Cleveland Clinic, as the next Co-Editors-in-Chief of HEPATOLOGY.
HEPATOLOGY, the premier publication in the field of liver disease, publishes original, peer-reviewed research across the full spectrum of hepatology, including immunology, chronic and viral hepatitis, cirrhosis, genetic and metabolic liver diseases, liver cancer, alcohol-associated liver disease, and drug metabolism. Its Editorial Board selects the most impactful advances in basic, translational, and clinical science each month.
“HEPATOLOGY is one of AASLD’s leading scientific journals that plays a critical role in shaping the future of liver research,” said Grace L. Su, MD, FAASLD, AASLD President. “We are thrilled to welcome Drs. Chalasani and Nagy as the next Co-Editors-in-Chief. Their scientific leadership, editorial experience, and deep commitment to advancing hepatology will continue to elevate the journal’s global impact. We are confident they will guide HEPATOLOGY into an exciting new era.”
About the Incoming Editors
Naga Chalasani, MD, FAASLD
Dr. Chalasani serves as the David W. Crabb Professor of Medicine and Director of the Terance Kahn Liver Research Program at Indiana University School of Medicine. He has held multiple leadership positions within Indiana University Health and IU School of Medicine and has maintained continuous NIH funding since 1999. His research focuses on metabolic dysfunction–associated steatotic liver disease (MASLD) and drug-induced liver injury (DILI).
He is a founding principal investigator of the NIDDK-funded NASH Clinical Research Network and the Drug-Induced Liver Injury Network and serves as PI for the HIV NASH CRN. Dr. Chalasani is an elected member of Alpha Omega Alpha, the American Society for Clinical Investigation, the American Association of Physicians, and the National Academy of Medical Sciences (India).
Laura E. Nagy, PhD, FAASLD
Dr. Nagy is Professor of Molecular Medicine and Staff in Inflammation and Immunity and Gastroenterology and Hepatology at the Cleveland Clinic, where she also directs the Liver Disease Research Center at the Lerner Research Institute. She holds adjunct faculty appointments at Case Western Reserve University and Cleveland State University.
Her research program focuses on signal transduction and innate immunity in MASLD and alcohol-associated liver diseases and has been continuously funded by the NIH and the Department of Defense. Dr. Nagy is a recipient of an NIH MERIT Award and is the principal investigator for the NIAAA-funded P50 Northern Ohio Alcohol Research Center. She previously served as Associate Editor for HEPATOLOGY and Alcoholism: Clinical and Experimental Research, and as Chair of the Board of Scientific Counselors and member of the Advisory Council for the National Institute on Alcohol Abuse and Alcoholism (NIAAA).
A Shared Vision for HEPATOLOGY
The incoming Co-Editors-in-Chief emphasized their commitment to excellence:
“Our vision is to make HEPATOLOGY the highest-ranked liver journal in the world. We will continue to build on the exceptional work done by Dr. Greg Gores and his Editorial Team in communicating the best research in hepatology over the last five years. Our team will be diverse and global, with deep scientific expertise, and we will be highly responsive to our stakeholders. HEPATOLOGY will remain a key forum for publishing outstanding basic and clinical advances in liver research.”
Drs. Chalasani and Nagy will begin reviewing manuscript submissions in July 2026, ahead of their five-year term beginning in January 2027.
AASLD extends its sincere appreciation to Gregory J. Gores, MD, FAASLD, the outgoing Editor-in-Chief, whose leadership has significantly expanded the journal’s impact and reach.
Learn more about HEPATOLOGY and follow the journal on X at @HEP_Journal.
About HEPATOLOGY
HEPATOLOGY publishes original, peer-reviewed articles on all aspects of liver structure, function, and disease. Each month, the journal highlights high-impact research spanning immunology, chronic hepatitis, viral hepatitis, cirrhosis, metabolic liver diseases, liver cancer, alcohol-associated liver disease, and drug metabolism.
About AASLD
The American Association for the Study of Liver Diseases (AASLD) is the leading organization of scientists and health care professionals dedicated to preventing and curing liver disease. AASLD advances the science and practice of hepatology through research, professional education, clinical guidance, publishing, and global collaboration.
###